Ziihera (zanidatamab-hrii) / Jazz 
Welcome,         Profile    Billing    Logout  
 0 Diseases   10 Trials   10 Trials   233 News 
22 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ziihera (zanidatamab-hrii) / Jazz
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
HERIZON-BTC-302, NCT06282575: Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

Recruiting
3
286
Europe, Canada, Japan, US, RoW
Zanidatamab, ZW25, JZP598, Cisplatin, Gemcitabine, Pembrolizumab, Durvalumab
Jazz Pharmaceuticals
Biliary Tract Cancer, HER2 Gene Mutation
07/28
11/29
BGB-A317-290-LTE1, NCT04164199 / 2019-002554-23: Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

Enrolling by invitation
3
300
Europe, Japan, US, RoW
Tislelizumab, BGB-A317, Pamiparib, BGB-290, Temozolomide, Sitravatinib, Ociperlimab, BGB-A1217, BAT1706, Fruquintinib, BGB-15025, Zanidatamab, ZW25, BGB-A445, Surzebiclimab, Lenvatinib, LBL-007
BeiGene
Advanced Malignancies
12/26
12/26
JZP598-303, NCT06435429: A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Recruiting
3
550
Europe, Canada, Japan, US, RoW
Zanidatamab, Trastuzumab, Eribulin, Vinorelbine, Gemcitabine, Capecitabine
Jazz Pharmaceuticals
Metastatic HER2-positive Breast Cancer
09/28
11/31
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
2019-002956-18: Study to evaluate the safety and tolerability of ZW25 in combination with palbociclib plus fulvestrant Estudio para evaluar la seguridad y tolerabilidad de ZW25 en combinación con palbociclib más fulvestrant

Not yet recruiting
2
76
Europe
ZW25, Ibrance, Fulvestrant, ZW25, Concentrate for solution for injection/infusion, Capsule, hard, Solution for injection, Ibrance, Faslodex
Zymeworks Inc., Zymeworks Inc.
Breast cancer patients including those with locally advanced (unresectable) or metastatic HER2-positive, HR-positive breast cancer. Pacientes con cáncer de mama incluyendo a aquellos con localmente avanzado (irresecable) y/o metastásico positivo para el receptor 2 del factor de crecimiento epidérmico humano (HER2) y positivo para receptores hormonales (RH)., Breast Cancer patients with locally advanced or metastatic cancer, that overexpress HER2 protein (receptor for the Human epidermal growth factor receptor 2), and are hormone receptor positive Pacientes con cáncer de mama localmente avanzado o metastásico, que sobreexpresan la proteína HER2 (receptor 2 del factor de crecimiento epidérmico humano) y son receptores de hormonas positivos, Diseases [C] - Cancer [C04]
 
 
ZWI-ZW25-202, NCT04224272: A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer

Active, not recruiting
2
51
Europe, Canada, US
ZW25 (Zanidatamab), Palbociclib, Fulvestrant
Jazz Pharmaceuticals
HER2+/HR+ Breast Cancer
04/23
10/25
HERIZON-BTC-01, NCT04466891 / 2020-000459-11: A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers

Completed
2
87
Europe, Canada, US, RoW
ZW25 (Zanidatamab), JZP598
Jazz Pharmaceuticals, BeiGene, Ltd.
HER2-amplified Biliary Tract Cancers
07/23
07/24
ZW25-IST-2, NCT04513665: ZW25 in Women With Endometrial Cancers

Completed
2
16
US
ZW25
Memorial Sloan Kettering Cancer Center, Zymeworks BC Inc.
Endometrial Cancer, Carcinosarcoma
03/24
03/24
NCT05270889: Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial

Not yet recruiting
2
50
RoW
Tislelizumab+Zanidatamab
Yonsei University
HER2-positive Gastric Cancer
06/24
06/24
NCT05035836: A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

Recruiting
2
20
US
Zanidatamab, ZW25, Letrozole, Tamoxifen
M.D. Anderson Cancer Center, Zymeworks BC Inc.
Breast Cancer, HER2-positive
12/25
12/25
NCT06695845: A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Recruiting
2
200
US
Zanidatamab, ZW25, JZP598
Jazz Pharmaceuticals, Jazz Pharmaceuticals Ireland Limited
Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression
12/26
12/27
ZWI-ZW25-201, NCT03929666: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer

Active, not recruiting
2
74
Canada, US, RoW
ZW25 (Zanidatamab), Capecitabine, Cisplatin, Fluorouracil, Leucovorin, Oxaliplatin, Bevacizumab, Gemcitabine
Jazz Pharmaceuticals
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
07/25
07/25
NCT06043427: Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma

Recruiting
2
168
Canada
Paclitaxel, Ramucirumab, Zanidatamab
Canadian Cancer Trials Group, Jazz Pharmaceuticals
Gastroesophageal Adenocarcinoma
12/25
06/26
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole, ARV-471 + Abemaciclib, Endoxifen + Abemaciclib, Rilvegostomig + TDXd, Dan222 + Niraparib, Sarilumab + Cemiplimab + Paclitaxel
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
BGB-A317-ZW25-101, NCT04276493: Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

Completed
1/2
71
RoW
Zanidatamab, ZW25, Docetaxel, Tislelizumab, BGB-A317, Capecitabine, Oxaliplatin
BeiGene
Breast Cancer, Gastric Cancer, Gastroesophageal Junction Cancer
12/23
10/24
ZWI-ZW25-204, NCT05027139: A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

Active, not recruiting
1/2
52
US
Zanidatamab, ZW25, JZP598, Evorpacept, ALX148
Jazz Pharmaceuticals, ALX Oncology Inc.
HER2-expressing Cancers
04/25
09/25
ZWI-ZW25-101, NCT02892123: Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers

Completed
1
279
Canada, US, RoW
ZW25 (Zanidatamab), Paclitaxel, Capecitabine, Vinorelbine, Tucatinib
Jazz Pharmaceuticals
HER2-expressing Cancers
10/24
10/24
PRE-I-SPY-PI, NCT05868226: PRE-I-SPY Phase I/Ib Oncology Platform Program

Recruiting
1
54
US
ALX148, Evorpacept, Fam-Trastuzumab Deruxtecan-Nxki, Enhertu, T-DXd, Zanidatamab, ZW25, zani, Tucatinib, TUKYSA
QuantumLeap Healthcare Collaborative
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer
12/26
12/27
JRCT2031210161: A Study of Zanidatamab in Japanese Subjects With Locally Advanced or Metastatic HER2-Expressing Cancers

Recruiting
N/A
48
Japan
zanidatamab zovodotin (ZW49) - Zymeworks
Zymeworks BC Inc.
Locally advanced (unresectable) and/or metastatic HER2-expressing cancer; cancer
 
 
NCT04578444: An Expanded Access Treatment Protocol of Zanidatamab (ZW25) in Patients With HER2-Positive Advanced Biliary Tract Cancer

Available
N/A
Europe, US
Zanidatamab, ZW25
Jazz Pharmaceuticals
HER2-Positive Advanced Biliary Tract Cancer
 
 
ChiCTR2000036161: Exploratory clinical study of ZW25 in the treatment of advanced biliary tract tumors

Recruiting
N/A
100
 
ZW25 20 mg/kg, IV Q2W ;ZW25 20 mg/kg, IV Q2W
Affiliated Third Hospital of Navy Medical University; Affiliated Third Hospital of Navy Medical University, Shanghai three year action plan for promoting clinical skills and clinical innovation in municipal hospitals
biliary tract tumors
 
 

Download Options